Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Nasdaq  >  OpGen, Inc.    OPGN


SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

OpGen : Corporate Presentation (PDF)

07/07/2020 | 08:39am EST


Corporate Overview

July 2020

Forward looking statements disclaimer

This presentation contains forward-looking statements that are subject to many risks and uncertainties. These statements, among other things, relate to our business strategy, goals and expectations concerning our products, future operations, prospects, plans and objectives of management. The words "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "plan," "predict," "project," "will" and similar terms and phrases are used to identify forward-looking statements in this presentation. These statements and other statements regarding our future plans constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1955. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond OpGen's control, and that may cause results to differ materially from expectations.

Factors that could cause results to differ materially from those described include, but are not limited to, our ability to successfully, timely and cost-effectively develop, seek and obtain regulatory clearance for and commercialize our product and service offerings, the rate of adoption of our products and services by hospitals and other healthcare providers, the realization of expected synergies from our business combination transaction with Curetis GmbH, the successful integration of our company with the operations and business of Curetis GmbH and its subsidiaries and the implementation of the combined company's strategic and business goals and objectives, the impact of COVID-19 on our operations, financial results, and commercialization efforts as well as on capital markets and general economic conditions, the ability to comply with the complexities of operating a global business, the success of our commercialization efforts, the effect on our business of existing and new regulatory requirements, and other economic and competitive factors. For a discussion of the most significant risks and uncertainties associated with OpGen's business, please review our filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which are based on our expectations as of the date of this presentation and speak only as of the date of this presentation. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

Recent newsflow

OpGen has recently announced several key updates and milestones

  • OpGen Releases Preliminary Data from Collaboration with Karolinska Institute, Stockholm, Sweden. Investigator-initiated clinical study demonstrates that Unyvero HPN Panel for Pneumonia Identifies Life-Threatening Bacterial Co-Infections in COVID-19 Patients in Just Five Hours

  • OpGen expands partnership with New York State Department of Health and IDC to detect antimicrobial resistant infections

  • OpGen publishes first quarter 2020 financial results and provides business update

  • Ares Genetics and Mayo Clinic publish validating data on feasibility of NGS-based AMR prediction

  • OpGen and Curetis complete business combination

OpGen and its group companies:

Striving to innovate molecular microbiology





Rapid Pathogen Detection For Life Threatening Infections

Broad Pathogen & Antimicrobial Resistance (AMR) Marker Coverage

AI-Powered AMR Prediction & Bioinformatics

Sample-To-Answer Platforms

Combined company's portfolio: Synergistic products & capabilities

Unyvero Platform & Syndromic Tests

Acuitas Tests & Acuitas Lighthouse

Global Commercial


Ares Genetics NGS &


Direct sales in U.S., European and China distribution with partners; 18 distributors covering 43 countries; CoV-2 test kit distribution in EMEA

Unyvero FDA-cleared platform for lower respiratory tract infection (LRT & LRT BAL) as well as 5 CE IVD tests; Unyvero A30 RQ platform in development

Acuitas AMR Gene Panel tests in clinical trials (Urine) and pending FDA clearance (isolates) to improve antibiotic decision making;

Lighthouse knowledge base deployed for public health useAres Technology for AI-powered AMR prediction combining ARESdb with NGS; Strategic partnerships with globally leading IVD & pharma companies


OpGen Inc. published this content on 07 July 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 07 July 2020 12:38:05 UTC

© Publicnow 2020
All news about OPGEN, INC.
11/24OPGEN INC : Entry into a Material Definitive Agreement, Unregistered Sale of Equ..
11/24OPGEN : Announces $10 Million Private Placement Priced at the Market
11/24OpGen, Inc. Announces $10 Million Private Placement Priced at the Market
11/16OPGEN : Note 2 - Liquidity and management's plans
11/13OPGEN : Corporate Presentation (PDF)
11/13OPGEN INC : Entry into a Material Definitive Agreement, Other Events, Financial ..
11/12OPGEN : Ares Genetics Commercially Launches NGS-based Antibiotic Resistance Test..
11/12OpGen Group Company Ares Genetics Commercially Launches NGS-based Antibiotic ..
11/12OPGEN INC : Results of Operations and Financial Condition, Financial Statements ..
11/11OPGEN : Reports Third Quarter 2020 Financial Results and Provides Business Updat..
More news
Financials (USD)
Sales 2020 4,12 M - -
Net income 2020 -24,8 M - -
Net Debt 2020 - - -
P/E ratio 2020 -1,16x
Yield 2020 -
Capitalization 39,5 M 39,5 M -
Capi. / Sales 2020 9,58x
Capi. / Sales 2021 3,53x
Nbr of Employees 39
Free-Float 99,9%
Duration : Period :
OpGen, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends OPGEN, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus HOLD
Number of Analysts 3
Average target price 5,33 $
Last Close Price 1,96 $
Spread / Highest target 188%
Spread / Average Target 172%
Spread / Lowest Target 155%
EPS Revisions
Oliver Schacht Chief Executive Officer & Director
Bill E. Rhodes Non-Executive Chairman
Johannes Bacher Chief Operating Officer
Timothy C. Dec CFO, Secretary & Chief Accounting Officer
Vadim Sapiro Chief Information Officer
Sector and Competitors
1st jan.Capitalization (M$)
OPGEN, INC.73.45%40
LONZA GROUP AG56.17%44 950
MODERNA, INC.403.89%39 001
CELLTRION, INC.82.32%36 284
SEAGEN INC.44.08%29 684